Suchen
Verona Pharma PLC
VRNAZur Watchlist hinzufügen
106.910USD
0.0000.00%
Handelsschluss 06/18, 16:00（ET）Kurse um 15 Minuten verzögert
73.55BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Verona Pharma PLC Unternehmen
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Verona Pharma PLC Informationen
BörsenkürzelVRNA
Name des UnternehmensVerona Pharma PLC
IPO-datumMar 30, 2005
CEODr. David S. Zaccardelli, Pharm.D.
Anzahl der mitarbeiter209
WertpapierartDepository Receipt
GeschäftsjahresendeMar 30
AddresseRiverside
StadtLONDON
BörseNASDAQ Global Market Consolidated
LandUnited Kingdom
PostleitzahlSE1 2RE
Telefon442032834200
Websitehttps://www.veronapharma.com/
BörsenkürzelVRNA
IPO-datumMar 30, 2005
CEODr. David S. Zaccardelli, Pharm.D.
Führungskräfte von Verona Pharma PLC
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
528.82K
+0.66%
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Dr. Anders Ullman, M.D., Ph.D.
Dr. Anders Ullman, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Benjamin Lucas
Mr. Benjamin Lucas
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Ebru Can Temucin
Ms. Ebru Can Temucin
Principal Financial Officer, Principal Accounting Officer, Director
Principal Financial Officer, Principal Accounting Officer, Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
528.82K
+0.66%
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Dr. Anders Ullman, M.D., Ph.D.
Dr. Anders Ullman, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Benjamin Lucas
Mr. Benjamin Lucas
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Ebru Can Temucin
Ms. Ebru Can Temucin
Principal Financial Officer, Principal Accounting Officer, Director
Principal Financial Officer, Principal Accounting Officer, Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Verona Pharma PLC?
Die fünf größten Anteilseigner von Verona Pharma PLC sind: Mr. Andrew Fisher
Wie viele Institutionen halten Anteile an Verona Pharma PLC (VRNA)?
Mit Stand vom 2025Q3 halten 467 Institutionen Anteile an Verona Pharma PLC, mit einem Gesamtmarktwert von etwa 76.61M, was 88.88% der Gesamtanteile entspricht. Im Vergleich zum 2025Q2 ist der institutionelle Aktienbesitz um -7116945.00 gestiegen.
